These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22498670)

  • 1. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
    Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
    Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
    Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
    Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
    Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.
    Montoya-Cerrillo D; Briski LM; Jorda M; Kryvenko ON
    Int J Surg Pathol; 2022 May; 30(3):260-264. PubMed ID: 34665053
    [No Abstract]   [Full Text] [Related]  

  • 7. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
    Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
    Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium.
    Yin H; He Q; Li T; Leong AS
    Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):260-5. PubMed ID: 16932015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
    Mallofré C; Castillo M; Morente V; Solé M
    Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
    Yin M; Bastacky S; Parwani AV; McHale T; Dhir R
    Hum Pathol; 2008 Apr; 39(4):527-35. PubMed ID: 18234280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
    Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
    Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
    Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
    Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
    Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial dysplasia of the bladder: diagnostic features and clinical significance.
    Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L
    Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of atypical papillary urothelial hyperplasia.
    Swierczynski SL; Epstein JI
    Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
    Fichtenbaum EJ; Marsh WL; Zynger DL
    Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypia in inverted urothelial papillomas: pathology and prognostic significance.
    Broussard JN; Tan PH; Epstein JI
    Hum Pathol; 2004 Dec; 35(12):1499-504. PubMed ID: 15619209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.